Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Drugs

Volumn 76, Issue 9, 2016, Pages 925-945

  Festino, Lucia ^a   Botti, Gerardo ^a   Lorigan, Paul ^b   Masucci, Giuseppe V ^c   Hipp, Jason D ^d   Horak, Christine E ^d   Melero, Ignacio ^e   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; BMS 936559; DURVALUMAB; IPILIMUMAB; MEDI 0680; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

BLADDER CANCER; CANCER THERAPY; COLORECTAL CANCER; DRUG ACTIVITY; DRUG EFFICACY; FUNCTIONAL STATUS; HEAD AND NECK CANCER; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY CARCINOMA; KIDNEY METASTASIS; LARGE CELL LYMPHOMA; LUNG CANCER; MELANOMA; METASTATIC MELANOMA; MICROSATELLITE INSTABILITY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PATIENT SELECTION; PROTEIN EXPRESSION; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR CELL; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT SELECTION; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84969921308     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0588-x     Document Type: Review

References (108)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
3. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
4. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44.
5. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31(15_suppl):9010 (ASCO meeting abstracts, 17 June 2013: abstract 9010).
6. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Jedd D. Wolchok, et al. Efficacy and safety of the anti-PD-1 monoclonalantibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;suppl:abstr LBA9000.
7. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
9. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.
10. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.
11. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.
12. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62.
13. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;suppl:abstr LBA9003^(32).
14. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.
15. Plimack ER, Hammers HJ, Rini BI, McDermott DF, Redman B, Kuzel T, et al. Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015;33(15_suppl):4553 (ASCO meeting abstracts, 18 May 2015: abstract 4553).
16. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Ernstoff M, et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015;33(15_suppl):4516 (ASCO meeting abstracts, 18 May 2015: abstract 4516).
17. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J Clin Oncol. 2016;34:833–42.
18. Amin A, Plimack ER, Infante JR, Ernstoff M, Rini BI, McDermott DF, et al. Nivolumab (n) (anti-pd-1; bms-936558, ono-4538) in combination with sunitinib (s) or pazopanib (p) in patients (pts) with metastatic renal cell carcinoma (mrcc). Ann Oncol. 2014;25(Supplement 4):iv361–372.
19. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27.
20. Sawnn JB, Smyth MJ. Immune surveillance of tumors. J Clin Investig. 2007;117:1137–46.
21. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136–51.
22. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.
23. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: efficacy and safety results from the EORTC 18071 phase III trial. Asia Pac J Clin Oncol. 2014;10:175.
24. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42.
25. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695–710.
26. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
27. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci. 1990;87:5031–5.
28. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, et al. Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology. 2015;4:e998538.
29. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.
30. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
31. Habicht A, Dada S, Jurewicz M, Fife BT, Yagita H, Azuma M, et al. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol. 2007;179:5211–9.
32. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90.
33. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94. doi:10.1200/JCO.2014.56.2736.
34. Weber JS, Minor DR, D’Angelo S, Hodi FS, Gutzmer R, Neyns B, et al. A phase 3 randomized, open-label study of nivolumab (anti-pd-1; bms-936558;ono4538) versus investigator’s choice chemotherapy (icc) in patients with advanced melanoma after prior anti-CTLA- 4 therapy. Ann Oncol. 2014;25 (suppl 4).
35. Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol. 2012;30(15).
36. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521–32.
37. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.
38. Soria J-C, Gettinger S, Gordon M, Heist RS, Horn L, Spigel DR, et al. Biomarkers associated with clinical activity ofpd-l1 blockade in non-small cell lung cancer(nsclc) patients (pts) in a phase i study of MPDL3280A. Ann Oncol. 2014;5(Supplement 4):iv426–470.
39. Rizvi NA, Brahmer JR, Ou SHI, Segal NH, Khleif S, Hwu W-J, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_suppl):8032 (ASCO meeting abstracts, 18 May 2015: abstract 8032).
40. Joaquim Bellmunt, Shilpa Gupta, Raanan Berger, Robert B. Montgomery, Karl Heath, Jonathan Juco, et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol. 2015;33(15_suppl):4502 (ASCO meeting abstracts, 18 May 2015: abstract 4502).
41. Seiwert TY, Haddad RI, Gupta S, Mehra R, Tahara M, Berger R, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015;33(15_suppl):LBA6008 (ASCO meeting abstracts, 18 May 2015: abstract LBA6008).
42. Fury SIO, A. Balmanoukian, A. Hansen, E. Massarelli, A. Blake-Haskins, X. Li, et al. Clinical activity and safety of medi4736, an anti-pd-l1 antibody, in patients with head and neck cancer. Ann Oncol. 2014;25(Supplement 4):iv340–356.
43. Amin A, Plimack ER, Infante JR, Ernstoff M, Rini BI, McDermott DF, et al. Nivolumab (n) (anti-pd-1; bms-936558, ono-4538) in combination with sunitinib (s) or pazopanib (p) in patients (pts) with metastatic renal cell carcinoma (mrcc). Ann Oncol. 2014;25(suppl 4):iv362–3.
44. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
45. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.
46. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089–96.
47. Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014;32:5s, (suppl; abstr 9002).
48. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31:4311–8.
49. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J Clin Oncol. 2015;33:2004–12.
50. Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer JR, Quan Man Chow L, et al First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. J Clin Oncol. 2015;33(suppl):abstr 8025.
51. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–65.
52. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.
53. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
54. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.
55. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, et al. Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab. J Clin Oncol. 2015;33(15_suppl):5570 (ASCO meeting abstracts, 18 May 2015: abstract 5570).
56. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
57. Hodi FS, Gibney G, Sullivan R, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder E, Ruisi M, Kong G, Horak C, Weber JS. 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). Eur J Cancer. 2015;51(suppl 3):S721.
58. Antonia SJ, Gettinger SN, Quan MCL, Juergens RA, Borghaei H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol. 2014;32:5s, (suppl; abstr 8023).
59. Rizvi NA, Quan Man Chow L, Borghaei H, Shen Y, Harbison C, Alaparthy S, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol. 2014;32:5s, (suppl; abstr 8022).
60. Gettinger S, Rizvi N, Chow LQ, Borghaei H, Brahmer JR, Juergens R, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) or erlotinib (ERL) in advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2014;25(Supplement 4):iv361–372.
61. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.
62. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18.
63. Patnaik A, Socinski MA, Gubens MA, Gandhi L, Stevenson J, Bachman RD, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol. 2015;33(15_suppl):8011 (ASCO meeting abstracts, 18 May 2015: abstract 8011).
64. Papadimitrakopoulou V, Patnaik A, Borghaei H, Stevenson J, Gandhi L, Gubens MA, et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J Clin Oncol. 2015;33(suppl):abstr 8031.
65. Ott PA, Elez Fernandez MA, Hiret S, Kim D-W, Moss RA, Winser T, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J ClinOncol. 2015;33(15_suppl):7502 (ASCO meeting abstracts, 18 May 2015: abstract 7502).
66. Alley EW, Rhoda Molife L, Santoro A, Beckey K, Yuan S, Cheng JD, Piperdi B, et al. Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. Cancer Res. 2015;75:CT103. doi:10.1158/1538-7445.AM2015-CT103.
67. Doi T, Piha-Paul SA, Jalal SA, Mai-Dang H, Yuan S, Koshiji M, Csiki I, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. J Clin Oncol. 2015;33(15_suppl):4010 (ASCO meeting abstracts, 18 May 2015: abstract 4010).
68. Bang JY, Chung HC, Shankaran V, Geva R, Virgil D, Catenacci T, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33(15_suppl):4001 (ASCO meeting abstracts, 18 May 2015: abstract 4001).
69. Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1-positive advanced ovarian cancer: Interim results from a phase Ib study. J Clin Oncol. 2015;33(15_suppl):5510 (ASCO meeting abstracts, 18 May 2015: abstract 4001).
70. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Abstract S1-09: a phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 2015;75(9 Supplement):S1–09.
71. Moskowitz CH, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Martin G. PD-1 Blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood. 2014;124(21):abstract 290.
72. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206.
73. Atkins MB, Kudchadkar R, Mario S, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol 2014;32:5s, (suppl; abstr 9001).
74. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria J-C, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31(15_suppl):3000 (ASCO meeting abstracts, 17 June 2015: abstract 3000).
75. Horn L, Spigel DR, Gettinger SN, Antonia SJ, Gordon MS, Herbst RS, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J Clin Oncol. 2015;33(15_suppl):8029 (ASCO meeting abstracts, 18 May 2015: abstract 8029).
76. Spira AI, Park K, Mazières J, Vansteenkiste JF, Rittmeyer A, Ballinger M, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol. 2015;33(15_suppl):8010 (ASCO meeting abstracts, 18 May 2015: abstract 8010).
77. Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Zambrano CC, et al. phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol. 2015;33(15_suppl):4501 (ASCO meeting abstracts, 18 May 2015: abstract 4501).
78. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
79. McDermott DF, Sznol M, Sosman JA, Soria J-C, Gordon MS, Hamid O, et al. Immune correlates and long term follow up of a phase ia study of mpdl3280a, an engineered pd-l1 antibody, in patients with metastatic renal cell carcinoma (mrcc). Ann Oncol. 2014;25(Supplement 4):280–304.
80. Lieu C, Bendell J, Powderly JD, Pishvaian MJ, Hochster H, Eckhardt SG, et al. Safety and efficacy of mpdl3280a (anti-pdl1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) wit locally advanced or metastatic solid tumors. Ann Oncol. 2014;25(Supplement 4):iv361–372.
81. Segal H, Ou S-HI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Blake-Haskins, Marcus O. Butler. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol. 2015;33(15_suppl):3011 (ASCO meeting abstracts, 18 May 2015: abstract 3011).
82. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Xia Li JV, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 2014;32:5s, (suppl; abstr 3002^).
83. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–74.
84. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.
85. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
86. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2014. doi:10.1111/pcmr.12340.
87. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.
88. Topalian SL, Sznol M, Brahmer JR, McDermott DF, Smith DC, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. J Clin Oncol. 2013;31(15_suppl):3002 (ASCO meeting abstracts, 17 June 2015: abstract 3002).
89. Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol. 2013;31(15_suppl):3016 (ASCO meeting abstracts, 17 June 2015: abstract 3016).
90. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32:5s, (suppl; abstr 3005^).
91. Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31(15_suppl):8008 (ASCO meeting abstracts, 17 June 2015: abstract 8008).
92. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46.
93. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800 [Erratum, Nat Med 2002;8:1039].
94. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99:12293–7.
95. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.
96. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10:1185–92.
97. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.
98. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–8.
99. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci. 2004;101:17174–9.
100. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117:2192–201.
101. Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol. 2013;14:152–61.
102. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–65.
103. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.
104. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014;153:145–52.
105. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer–response. Clin Cancer Res. 2013;19(19):5542.
106. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.
107. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–81.
108. Spranger S, Bao R, Gajewski T. Melanoma-intrinsic b-catenin signaling prevents T cell infiltration and anti-tumor immunity. J Immunother Cancer. 2014;2(Suppl 3):O15.